Sökning: onr:"swepub:oai:DiVA.org:uu-518748" >
Secondary malignanc...
-
Abalo, KossiUppsala University,Karolinska Institute,Uppsala universitet,Cancerprecisionsmedicin,Karolinska Inst, Dept Med Solna, Clin Epidemiol Div, Stockholm, Sweden.
(författare)
Secondary malignancies among mantle cell lymphoma patients
- Artikel/kapitelEngelska2023
Förlag, utgivningsår, omfång ...
-
Elsevier,2023
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-518748
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-518748URI
-
https://doi.org/10.1016/j.ejca.2023.113403DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:154368681URI
-
https://lup.lub.lu.se/record/8261b5b0-3f5f-46d6-b2f3-2b2d3c32f014URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Purpose:With modern treatments, mantle cell lymphoma (MCL) patients more frequently experience long-lasting remission resulting in a growing population of long-term survivors. Follow-up care includes identification and management of treatment-related late-effects, such as secondary malignancies (SM). We conducted a populationbased study to describe the burden of SM in MCL patients.Methods:All patients with a primary diagnosis of MCL, aged >= 18 years and diagnosed between 2000 and 2017 in Sweden were included along with up to 10 individually matched population comparators. Follow-up was from twelve months after diagnosis/matching until death, emigration, or December 2019, whichever occurred first. Rates of SM among patients and comparators were estimated using the Anderson-Gill method (accounting for repeated events) and presented as hazard ratios (HR) with 95% confidence intervals (CI) adjusted for age at diagnosis, calendar year, sex, and the number of previous events.Results:Overall, 1 452 patients and 13 992 comparators were followed for 6.6 years on average. Among patients, 230 (16%) developed at least one SM, and 264 SM were observed. Relative to comparators, patients had a higher rate of SM, HRadj= 1.6 (95%CI:1.4-1.8), and higher rates were observed across all primary treatment groups: the Nordic-MCL2 protocol, R-CHOP, R-bendamustine, ibrutinib, lenalidomide, and R-CHOP/Cytarabine. Compared to Nordic-MCL2, treatment with R-bendamustine was independently associated with an increased risk of SM, HRadj= 2.0 (95%CI:1.3-3.2). Risk groups among patients were those with a higher age at diagnosis (p < 0.001), males (p = 0.006), and having a family history of lymphoma (p = 0.009). Patients had preferably higher risk of melanoma, other neoplasms of the skin and other hematopoietic and lymphoid malignancies.Conclusions:MCL survivors have an increased risk of SM, particularly if treated with R-bendamustine. The intensive treatments needed for long-term remissions are a concern, and transition to treatment protocols with sustained efficacy but with a lower risk of SM is needed.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Smedby, Karin E.Karolinska Institute,Karolinska Institutet,Karolinska University Hospital
(författare)
-
Ekberg, SaraKarolinska Institute(Swepub:lu)sa7767ek
(författare)
-
Eloranta, SandraKarolinska Institute
(författare)
-
Pahnke, SimonUppsala University,Uppsala universitet,Cancerprecisionsmedicin(Swepub:uu)simpa740
(författare)
-
Albertsson-Lindblad, AlexandraLund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lymfom - Klinisk forskning,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Lymphoma - Clinical Research,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments(Swepub:lu)med-aab
(författare)
-
Jerkeman, MatsLund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lymfom - Klinisk forskning,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Onkologi övergripande,Institutionen för kliniska vetenskaper, Lund,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Lymphoma - Clinical Research,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Oncology corporate,Department of Clinical Sciences, Lund(Swepub:lu)onk-mje
(författare)
-
Glimelius, Ingrid,1975-Uppsala University,Karolinska Institute,Karolinska Institutet,Uppsala universitet,Cancerprecisionsmedicin,Karolinska Inst, Dept Med Solna, Clin Epidemiol Div, Stockholm, Sweden.(Swepub:uu)inggl846
(författare)
-
Uppsala universitetCancerprecisionsmedicin
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:European Journal of Cancer: Elsevier1950959-80491879-0852
Internetlänk
Hitta via bibliotek
Till lärosätets databas